Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
作者： Vanda Salutari , Giovanni Scambia , Saverio Cinieri , Sandro Pignata , Isabelle Ray-Coquard
DOI: 10.1016/S1470-2045(20)30637-9
关键词:
摘要: … 1, every 28 days), or a carboplatin-based doublet plus bevacizumab (10 mg/kg … carboplatin, or 15 mg/kg every 21 days combined with gemcitabine–carboplatin or paclitaxel–carboplatin)…
elsevier.com
sci-hub.st 参考文章(16)
Michael Schemper, Terry L. Smith, A note on quantifying follow-up in studies of failure time Controlled Clinical Trials. ,vol. 17, pp. 343- 346 ,(1996) , 10.1016/0197-2456(96)00075-X
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
Ignace Vergote, Eric Pujade-Lauraine, Sandro Pignata, Gunnar B. Kristensen, Jonathan Ledermann, Antonio Casado, Jalid Sehouli, Mansoor Mirza, Roldano Fossati, Christian Marth, Carine Creutzberg, Jose Del Campo, Nadeem Siddiqui, Paula Calvert, Aris Bamias, Gokhan Tulunay, Ate G.J. van der Zee, Andreas du Bois, European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies International Journal of Gynecological Cancer. ,vol. 20, pp. 476- 478 ,(2010) , 10.1111/IGC.0B013E3181D3CAA8
TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, G Kristensen, MS Carey, P Beale, A Cervantes, C Kurzeder, A du Bois, J Sehouli, R Kimmig, A Stähle, F Collinson, S Essapen, C Gourley, A Lortholary, F Selle, MR Mirza, A Leminen, M Plante, D Stark, W Qian, AM Parmar, MK: Oza, ICON7 Investigators, None, A phase 3 trial of bevacizumab in ovarian cancer. The New England Journal of Medicine. ,vol. 365, pp. 2484- 2496 ,(2011) , 10.1056/NEJMOA1103799
Dan Stark, Matthew Nankivell, Eric Pujade-Lauraine, Gunnar Kristensen, Lorraine Elit, Martin Stockler, Felix Hilpert, Andrés Cervantes, Julia Brown, Anne Lanceley, Galina Velikova, Eduardo Sabate, Jacobus Pfisterer, Mark S Carey, Philip Beale, Wendi Qian, Ann Marie Swart, Amit Oza, Tim Perren, Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial Lancet Oncology. ,vol. 14, pp. 236- 243 ,(2013) , 10.1016/S1470-2045(12)70567-3
Ettore Marubini, Marai Grazia Valsecchi, Analysing Survival Data from Clinical Trials and Observational Studies ,(1995)
Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang, Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer The New England Journal of Medicine. ,vol. 365, pp. 2473- 2483 ,(2011) , 10.1056/NEJMOA1104390
Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg, Claus-Christoph Steffens, Vicente Alonso-Orduña, Christoph Schlichting, Irmarie Reyes-Rivera, Belguendouz Bendahmane, Thierry André, Stefan Kubicka, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncology. ,vol. 14, pp. 29- 37 ,(2013) , 10.1016/S1470-2045(12)70477-1
Mansoor Raza Mirza, Philippe Follana, David Bollag, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial Journal of Clinical Oncology. ,vol. 32, pp. 1302- 1308 ,(2014) , 10.1200/JCO.2013.51.4489
Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff, Patricia L. Judson, Michael G. Teneriello, Amreen Husain, Mika A. Sovak, Jing Yi, Lawrence R. Nycum, OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Journal of Clinical Oncology. ,vol. 30, pp. 2039- 2045 ,(2011) , 10.1200/JCO.2012.42.0505